Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (6) Blankenstein, Thomas Prof. Dr. (179) Bunse, Mario Dr. (3) Cakmak-Görür, Nese Dr. (1) Clauß, Julian (1) Daniel, Peter Prof. Dr. (4) Dhamodaran, Arunraj (2) Dyck, Lydia Dr. (1) Filosa, Alessandro Dr. (1) Gerhardt, Holger Prof. Dr. (1) Henssen, Anton Prof. Dr. med. (1) Höpken, Uta Elisabeth PD Dr. (2) Hübner, Norbert Prof. Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (1) Jeuthe, Sarah Dr. (1) Kammertöns, Thomas Dr. (38) Keller, Ulrich Dr. med. (1) Kieback, Elisa Dr. (3) Kühn, Ralf Dr. (1) Kunz, Severine Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (10) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Mertins, Philipp Dr. (3) Na, Il-Kang Dr. (2) Nguyen, Tam Hoai Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (17) Poncette, Lucia (4) Rahn, Hans-Peter Dr. (1) Rathjen, Fritz Prof. Dr. (1) Rehm, Armin Dr. (1) Rhein, Simone Dr. (2) Richter, Matthias (1) Rosenberger, Leonie Milena (1) Sawamiphak, Suphansa Dr. (1) Schlag, Peter M. Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Schütz, Anja Dr. (1) Siffrin, Volker (1) Sporbert, Anje Dr. (1) Stein, Ulrike Prof. Dr. (3) Uckert, Wolfgang Prof. Dr. (23) Walther, Wolfgang Prof. Dr. (7) Willimsky, Gerald Dr. (34) Wolf, Susanne Dr. (2) (-) Kopp, Joachim Dr. (5) (-) Popp, Oliver Dr. (3) Advanced Light Microscopy (1) Ankerproteine und Signaltransduktion (2) Bioinformatics and Omics Data Science (1) Biologie maligner Lymphome (1) Electron Microscopy (1) Entwicklung Mechanismus-basierter Krebstherapien (1) Flow Cytometry (1) Genetik und Genomik von Herz- Kreislauferkrankungen (4) Genom-Editierung & Krankheitsmodelle (2) Genomdiversifikation & Integrität (1) Immunregulation und Krebs (2) Integrative Vaskuläre Biologie (1) Intrazelluläre Proteolyse (1) Molekulare Herz- Kreislaufforschung (3) (-) Molekulare Immunologie und Gentherapie (8) Molekulare Onkologie (1) Myologie (1) Proteomforschung und molekulare Mechanismen bei neurodegenerativen Erkrankungen (1) Proteomics (29) Psychoneuroimmunologie (3) Strukturbiologie Membran-assoziierter Prozesse (1) Synaptische Transmission und Plastitzität (1) Transgenics (2) Translational Bioinformatics (2) Translationale Onkologie solider Tumore (3) Zelluläre Neurowissenschaften (4) 2005 (1) 2010 (1) 2011 (1) 2013 (1) 2015 (1) 2022 (2) 2023 (1) 8 Ergebnisse: Active Filter: Kopp, Joachim Dr.Popp, Oliver Dr.Molekulare Immunologie und Gentherapie Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. November 2022 / Cancer Immunol Res Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma C. Welters M.F. Lammoglia Cobo C.A. Stein M.T. Hsu A. Ben Hamza L. Penter X. Chen C. Buccitelli O. Popp P. Mertins K. Dietze L. Bullinger A. Moosmann E. Blanc D. Beule A. Gerbitz J. Strobel H. Hackstein H.P. Rahn K. Dornmair T. Blankenstein L. Hansmann 14. März 2023 / J Immunother Cancer Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al L. Immisch G. Papafotiou O. Popp P. Mertins T. Blankenstein G. Willimsky 27. Oktober 2022 / J Immunother Cancer H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma L. Immisch G. Papafotiou O. Popp P. Mertins T. Blankenstein G. Willimsky 15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann 01. Januar 2005 / Clin Cancer Res Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs B. Frankenberger H. Pohla E. Noessner G. Willimsky B. Papier A. Pezzutto J. Kopp R. Oberneder T. Blankenstein D.J. Schendel 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. November 2022 / Cancer Immunol Res Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma C. Welters M.F. Lammoglia Cobo C.A. Stein M.T. Hsu A. Ben Hamza L. Penter X. Chen C. Buccitelli O. Popp P. Mertins K. Dietze L. Bullinger A. Moosmann E. Blanc D. Beule A. Gerbitz J. Strobel H. Hackstein H.P. Rahn K. Dornmair T. Blankenstein L. Hansmann
14. März 2023 / J Immunother Cancer Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al L. Immisch G. Papafotiou O. Popp P. Mertins T. Blankenstein G. Willimsky
27. Oktober 2022 / J Immunother Cancer H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma L. Immisch G. Papafotiou O. Popp P. Mertins T. Blankenstein G. Willimsky
15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann
01. Januar 2005 / Clin Cancer Res Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs B. Frankenberger H. Pohla E. Noessner G. Willimsky B. Papier A. Pezzutto J. Kopp R. Oberneder T. Blankenstein D.J. Schendel
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto